Autoimmune Hemolytic Anemia clinical trials

Explore recruiting autoimmune hemolytic anemia clinical trials.

Recruiting autoimmune hemolytic anemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Autoimmune Hemolytic Anemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension

Hungary, Czechia, France, Greece, Netherlands, Poland +3 more

Phase II and Phase III (Integrated) EU CTIS Study details

API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH A SAFETY AND DOSE CONFIRMATION RUN-IN PERIOD, TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA (SAPHIARE)

Spain, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (LUMINA 2)

Italy, Spain, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Ibrutinib for the Treatment of Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis. CLL2323

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)

Italy, Denmark, Spain, France, Belgium, Poland +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Autoimmune Hemolytic Anemia trials by city

Autoimmune Hemolytic Anemia in Toronto Autoimmune Hemolytic Anemia in Vancouver Autoimmune Hemolytic Anemia in Montreal Autoimmune Hemolytic Anemia in Calgary Autoimmune Hemolytic Anemia in Edmonton Autoimmune Hemolytic Anemia in Ottawa Autoimmune Hemolytic Anemia in Winnipeg Autoimmune Hemolytic Anemia in Quebec City Autoimmune Hemolytic Anemia in Hamilton Autoimmune Hemolytic Anemia in Kitchener Autoimmune Hemolytic Anemia in London Autoimmune Hemolytic Anemia in Halifax Autoimmune Hemolytic Anemia in New York Autoimmune Hemolytic Anemia in Los Angeles Autoimmune Hemolytic Anemia in Chicago Autoimmune Hemolytic Anemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease